SC Plaque psoriasis Adult 300 mg given as 2 inj of 150 mg w/ initial dosing at wk 0, 1, 2, 3, & 4 followed by mthly maintenance dosing.
Ped ≥50 kg 150 mg (may be increased to 300 mg);
25-<50 kg 75 mg;
<25 kg 75 mg. Each 75 & 150 mg is given as 1 inj; each 300 mg is given as 2 inj of 150 mg w/ initial dosing at wk 0, 1, 2, 3, & 4 followed by mthly maintenance dosing.
Psoriatic arthritis 150 mg w/ initial dosing at wk 0, 1, 2, 3, & 4 followed by mthly maintenance dosing. Can be increased to 300 mg given as 2 inj of 150 mg based on clinical response.
Patient who are anti-TNFα inadequate responders or w/ concomitant moderate to severe plaque psoriasis 300 mg given as 2 inj of 150 mg w/ initial dosing at wk 0, 1, 2, 3, & 4 followed by mthly maintenance dosing.
Ankylosing spondylitis 150 mg w/ initial dosing at wk 0, 1, 2, 3, & 4 followed by mthly maintenance dosing. Can be increased to 300 mg given as 2 inj of 150 mg based on clinical response.
Non-radiographic axSpA 150 mg w/ initial dosing at wk 0, 1, 2, 3, & 4 followed by mthly maintenance dosing.
Sign Out
